No abstract available
MeSH terms
-
ADAM Proteins / deficiency
-
ADAM Proteins / immunology
-
ADAM Proteins / physiology
-
ADAMTS13 Protein
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Autoantibodies / immunology
-
Bevacizumab
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Neoplasms / blood
-
Neoplasms / drug therapy
-
Plasma Exchange
-
Postoperative Complications / etiology
-
Thrombotic Microangiopathies* / chemically induced
-
Thrombotic Microangiopathies* / epidemiology
-
Thrombotic Microangiopathies* / etiology
-
Thrombotic Microangiopathies* / physiopathology
-
Thrombotic Microangiopathies* / therapy
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Autoantibodies
-
Immunosuppressive Agents
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
ADAM Proteins
-
ADAMTS13 Protein
-
ADAMTS13 protein, human